SYNTARA LIMITED (SNT)
Share Price Analysis and Chart

18/12/2024

1

Speculative Buy

$0.12

50.00%

Bell Potter reports Syntara reported impressive interim Phase 2a data for its lead asset, SNT-5505, in myelofibrosis  including a strong clinical benefit, with 46% of patients achieving a 50% symptom improvement by week 12, increasing to 80% at week 38.

As per the broker, SNT-5505 demonstrated a favourable safety profile with no severe treatment-related adverse events and improvements in spleen size and blood parameters.

The company completed a $15m capital raise with funding now to June 2026 and remains on track for a Phase 2c/3 registrational trial. 

Speculative Buy rating retained. Target price is raised to 12c from 10.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.00 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.90 cents.

17/03/2025

1

Initiation of coverage with Buy

$0.25

212.50%

Canaccord Genuity has initiated coverage of Syntara with a Buy rating and target price of 25c.

The broker notes the company's SNT-5505 is being explored for myelofibrosis (MF), a rare blood cancer that is recognised as an orphan disease. This provides the benefit of faster regulatory review and higher pricing. 

Final result of the phase 2 trial is due 2Q2025 which could lead to engagement with the FDA for phase 3 trial, the broker notes.

The broker's valuation if the company is fully acquired now is US$270m or 25c/share. Post-phase 3, the broker's valuation increases to US$900m.